14 results about "Clot formation" patented technology

The present disclosure provides methods for using antibodies that bind to Factor XI (FXI) for the purpose of preventing or treating clot formation or thrombogenesis after a surgical procedure. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat or prevent clot formation in a subject requiring such treatment, such as, but not limited to, post-surgery.

The invention discloses a blood coagulation index detection system and method based on ultrasonic guided waves, and the method comprises the steps: calculating a blood coagulation index corresponding to a sample according to an obtained viscoelasticity change curve; comprising the following steps: the clot starting time is defined as the time interval from the time when a blood sample is placed in a blood clot index detection system to the time when initial fibrin starts to form, and the R time of a TEG detection result of a gold standard method is marked; the clot stabilization time is defined as the clot formation time of the blood sample and the K time of the TEG detection result of the gold standard method; the theta angle is used for measuring the generation and cross-linking speed of fibrin and the alpha angle of a TEG detection result of a gold standard method; the maximum clot strength is the MA value of the TEG detection result of the gold standard method. Compared with a TEG method, the method has the advantages that the detection time of blood coagulation indexes is remarkably shortened, time guarantee is provided for emergency blood coagulation function evaluation and reasonable application of blood products in an operation, and improvement of clinical prognosis is facilitated.

Viscoelastic coagulation monitoring systems having two glass discs mounted on flexible plastic arms for receiving a sample of blood therebetween, and an analyzer configured to measure a coagulation response of the sample of blood to determine whether the sample of blood indicates a hypercoagulable state in a HS patient are provided. The system may cause movement of a first glass disc relative to a second glass disc at a sufficient speed to cause coagulation of the sample of blood, and the analyzer may measure various parameters of the coagulation response including, e.g., Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (a-angle), Maximum Clot Firmness (MCF), Amplitude at 10 and 20 minutes (A10, A20, respectively), Lysis Index at 30 and 45 minutes (LI30 and LI45, respectively), indicative of a hypercoagulable state in a HS patient.

Provided are an instrument and a coating agent for use in blood vessels, which can be stably supplied, have excellent suppression of clot formation, and are unlikely to inhibit vascular endothelialization. The instrument according to the present invention comprises a base material and a coating layer that covers at least a part of the surface of the base material, and is intended to be used in a blood vessel. The coating layer has a monomolecular layer formed by treating the surface of the base material with a low-molecular-weight compound having a functional group such as an albumin-binding functional group, and satisfies at least one of predetermined requirements.

The present invention discloses an anti-factor V antibody useful as an anticoagulant agent and as a tool for diagnostic and research applications. The antibody or its fragments can be conveniently used as anticoagulant agents inhibiting Factor V and / or Factor Va, particularly to reduce clot formation and associated thrombotic events, or they can be used in vitro to measure the levels of Factor V in a blood sample. Other aspects of the invention regard nucleic acids encoding the antibody or fragments thereof as well as expression vectors and host cells containing them.

The invention discloses a lophatherum gracile extract in preparation of a medicine for treating and preventing thrombosis and application of the lophatherum gracile extract in preparation of the medicine for treating and preventing thrombosis, and the medicine comprises the lophatherum gracile extract. The common lophatherum herb extract can inhibit platelet agonist-induced platelet blood clot formation so as to prevent and treat thrombosis, and can inhibit a platelet agonist-induced platelet aggregation function so as to prevent and treat thrombosis. A platelet activation function induced by a platelet agonist can be inhibited so as to prevent and treat thrombosis, and platelet microtubule morphological change induced by the platelet agonist can be inhibited so as to prevent and treat thrombosis; the invention proves that the lophatherum gracile extract has the effects of inhibiting platelet aggregation, activation, particle release and microtubule morphological change for the first time, has small toxic and side effects, provides a new research and development direction for clinical treatment of thrombotic diseases, and shows that the lophatherum gracile extract can be used as a new type of health care product medicine for preventing thrombotic diseases.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and / or inhibit cell proliferation.

Methods of accelerating clot formation and increasing clot deposition in a hemophiliac subject. A vagal nerve stimulator (VNS) may be implanted in a hemophiliac subject. The hemophiliac subject may have developed antibodies to factor VIII and not been administered a clotting factor within the last 48 hours. The vagus nerve of the subject may be stimulated in a manner that increases platelet intracellular calcium and / or activates splenic acetylcholine-synthesizing T lymphocytes using the implanted VNS.

According to the method for intelligently preventing the formation of the pressure sores and the thrombus of the bedridden patient, the body position of the patient is effectively adjusted through the real-time monitoring and pressure reduction functions of the electronic induction pressure sore prevention hospital gown, the pressure of the pressed part is relieved, and the occurrence risk of the pressure sores is effectively reduced. The intelligent sensing system continuously monitors the blood circulation condition of a patient, when the blood flow rate is lower than the normal flow rate, early warning is given, the massage function of the hospital gown gives massage with corresponding strength according to the pressure condition, the blood flow rate is increased, and thrombosis is avoided. Massage parts comprise body pressed parts and four limbs, so that the comfort of the patient is improved. The intelligent sputum sensing part sensor senses the position information of the sputum of the patient, a nurse conducts back patting and sputum excretion according to the position information of the sputum of the patient, and the sputum excretion effect of the patient is effectively improved. The information provided by the invention is helpful for nursing personnel to select proper nursing measures, and the nursing quality is improved.

The present disclosure provides antibodies that bind to the catalytic domain of factor XI (FXI) and methods of use thereof. According to certain embodiments, the antibodies are antagonistic antibodies that inhibit clot formation via the intrinsic pathway without affecting hemostasis, as demonstrated by their ability to prolong aPTT without affecting PT. Thus, these antagonistic antibodies can be used in the treatment or therapeutic regimen of blood clotting diseases or disorders that have clot formation as a risk factor, such as, but not limited to, atrial fibrillation. In certain embodiments, the present disclosure includes antibodies that bind to FXI and mediate clot or thrombus formation. The antibodies of the present disclosure can be fully human, non-naturally occurring antibodies.

The invention provides RGD (arginine-glycine-aspartic acid) modified hydrogel and application thereof, relates to the technical field of biological materials, and has the technical key points that the RGD modified hydrogel is provided and is characterized in that the RGD modified hydrogel is prepared from a PEGDA (polyethylene glycol diacrylate) prepolymer, Irgacure 2959 and acryloylated RGD peptide. The application illustrates that aPL induces platelet aggregation, thrombosis and inflammatory response by activating alphaIIb beta3 integrin, and further damages the function of the trophoblast. The RGD functionalized hydrogel based on PEG and the alphaIIb beta3 antibody can significantly inhibit platelet aggregation (decreasing amplitude to 83%), delay fibrin clot formation (OD405 is reduced by 67%), and reduce release of inflammatory factors such as IL-6 / TNF-alpha (decreasing amplitude to 70-80%). More importantly, the intervention measures can protect the migration ability of the trophoblast, which is a key process of placenta vascular remodeling. The integrin targeting biological material strategy provides a new way for preventing and treating APS-related pregnancy complications through local antithrombotic and anti-inflammatory dual effects.

A medical instrument with little risk of clot formation even when blood is flowed therethrough, said medical instrument (1) comprising a plurality of blood channel layers (3), wherein the plurality of blood channel layers (3) each have a plate-shaped main body (5), a groove (9) for forming a blood channel (7), and a resin layer (11) formed on the side wall of the groove (9). A manufacturing method of the medical instrument comprises: a resin applying step for applying a resin to the groove (9) of the plate-shaped main body (5) having the groove (9) for forming the blood channel (7); a bonding step for sandwiching the plate-shaped main body (5) between a first film (41) and a second film (43) and thus bonding the plate-shaped main body (5), the first film (41) and the second film (43); and a post-curing step for, after the bonding step, curing the resin applied to the groove (9) in the resin applying step.

The invention discloses bioactive glass composite antibacterial hemostatic frozen gel sponge as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: adding EDC and NHS into an SA aqueous solution under continuous stirring, continuously stirring, adding ZnMBG into a CCS aqueous solution, uniformly dispersing, mixing and stirring the obtained mixed solution, pouring the mixed solution into a mold, standing at low temperature, carrying out primary crosslinking and freeze drying, soaking the obtained frozen gel into an anhydrous calcium chloride solution, carrying out secondary crosslinking, and carrying out freeze drying to obtain the hydrogel. And freeze-drying to obtain the product. The obtained sponge has a macroporous structure, can quickly absorb blood and form a physical barrier, activates a blood coagulation pathway by releasing Ca < 2 + > and Zn < 2 + >, and promotes red blood cell aggregation and blood clot formation; zn < 2 + > and positive groups of CCS are synergistically antibacterial, so that infection is prevented; the material has shape memory ability and biocompatibility, and is suitable for efficient hemostasis and infection control of incompressible wounds.